Table 1.
Baseline demographic and disease characteristics of the patients a
| Not maintained DAS28 (ESR) <2.6 for 24 weeks (n = 146) |
Maintained DAS28 (ESR) <2.6 for 24 weeks (n = 69) |
||||
|---|---|---|---|---|---|
| Discontinued ADA (n = 51) | P b | Continued ADA (control) (n = 18) | P c | ||
| Age, year |
61.1 ± 11.6 |
59.5 ± 11.2 |
0.3910 |
64.8 ± 10.4 |
0.0513 |
| Gender, F:M |
127:19 |
40:11 |
0.1742 |
14:4 |
1.0000 |
| Disease duration, year |
9.4 ± 10.3 |
7.1 ± 9.9 |
0.0356 |
6.7 ± 10.1 |
0.7375 |
| RF, U/mL |
137.2 ± 248.5 |
109.0 ± 143.0 |
0.5539 |
283.5 ± 550.5 |
0.1400 |
| TJC, 0 to 28 |
8.9 ± 6.7 |
8.1 ± 6.6 |
0.4014 |
7.6 ± 5.4 |
0.9727 |
| SJC, 0 to 28 |
7.5 ± 5.5 |
6.4 ± 5.0 |
0.1770 |
6.7 ± 4.5 |
0.6214 |
| PGA, 0 to 100 mm |
53.4 ± 24.8 |
39.0 ± 24.2 |
0.0008 |
47.8 ± 24.7 |
0.2185 |
| EGA, 0 to 100 mm |
39.6 ± 22.7d |
31.5 ± 21.3 |
0.0398 |
34.7 ± 19.6g |
0.4636 |
| CRP, mg/dl |
2.89 ± 4.07 |
2.27 ± 3.71 |
0.1460 |
1.61 ± 1.58 |
0.3817 |
| ESR, mm/hour |
51.9 ± 32.4 |
43.2 ± 33.6 |
0.0574 |
45.6 ± 25.0 |
0.4318 |
| DAS28 (ESR) |
5.57 ± 1.27 |
5.06 ± 1.26 |
0.0183 |
5.33 ± 1.25 |
0.3528 |
| MMP-3, ng/ml |
313 ± 363 |
217 ± 339 |
0.0301 |
333 ± 233 |
0.0005 |
| HAQ, 0 to 3 |
1.37 ± 0.77e |
0.91 ± 0.67 |
0.0003 |
1.27 ± 0.51h |
0.0295 |
| MTX, mg/wf | 8.85 ± 3.11 | 8.96 ± 2.72 | 0.8937 | 9.61 ± 1.97 | 0.3480 |
aExcept where indicated otherwise, values are the mean ± SD; bnot maintained DAS28 (ESR) <2.6 for 24 weeks versus maintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA; cmaintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA versus maintained DAS28 (ESR) <2.6 for 24 weeks/Continued ADA (control); dN = 72; eN = 143; fthe mean ± SD were determined including those without concomitant administration of MTX by handling as zero; gN = 10; hN = 16. CPR, C-reactive protein; DAS28, disease activity score; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, patient’s global assessment of disease activity; RF, rheumatoid factor; TJC; tender joint count; SJC, swollen joint count.